Health Care & Life Sciences » Biotechnology | Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
45.22 M
Public Float
33.52 M
Aerie Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$5.56
Market Cap
$1.19 B
Shares Outstanding
45.92 M
Public Float
40.44 M

Profile

Address
4301 Emperor Boulevard
Durham North Carolina 27703
United States
Employees -
Website http://www.aeriepharma.com
Updated 07/08/2019
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan. The company was founded by David L.

Financials

View All
Created with Highcharts 5.0.14Aerie Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values USD Thousands.31 14831 14848 13348 13374 36374 36399 05999 059145 105145 105232 569232 569201320142015201620172018050k100k150k200k250k

Vicente J. Anido
Chairman & Chief Executive Officer
Michael M. du Toit
Independent Director